Literature DB >> 10416747

Potential role of nitric oxide and endothelin in the pathogenesis of glaucoma.

I O Haefliger1, E Dettmann, R Liu, P Meyer, C Prünte, J Messerli, J Flammer.   

Abstract

Glaucoma is an optic nerve head neuropathy in which retinal ganglion cells are lost. A clear association exists between glaucoma and different risk factors, such as high intraocular pressure (IOP) or blood-flow dysregulation. Nitric oxide (NO) and endothelin, two recently identified cellular mediators, appear to be involved in the regulation of IOP as well as in the modulation of ocular blood flow. To some extent, NO is also involved in apoptosis, a mechanism of cell death that can lead to retinal ganglion cell loss in glaucoma. This article provides a short and simplified overview of the biochemistry of NO and endothelin and highlights the potential role of these two mediators in certain important aspects related to the pathogenesis of glaucoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10416747     DOI: 10.1016/s0039-6257(99)00026-0

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  24 in total

1.  Effect of nimodipine on ocular blood flow and colour contrast sensitivity in patients with normal tension glaucoma.

Authors:  A Luksch; G Rainer; D Koyuncu; P Ehrlich; T Maca; M E Gschwandtner; C Vass; L Schmetterer
Journal:  Br J Ophthalmol       Date:  2005-01       Impact factor: 4.638

2.  The role of lipid dysregulation and vascular risk factors in glaucomatous retrobulbar circulation.

Authors:  Monika Modrzejewska; Wilhelm Grzesiak; Daniel Zaborski; Anna Modrzejewska
Journal:  Bosn J Basic Med Sci       Date:  2015-03-15       Impact factor: 3.363

3.  Vascular tone pathway polymorphisms in relation to primary open-angle glaucoma.

Authors:  J H Kang; S J Loomis; B L Yaspan; J C Bailey; R N Weinreb; R K Lee; P R Lichter; D L Budenz; Y Liu; T Realini; D Gaasterland; T Gaasterland; D S Friedman; C A McCarty; S E Moroi; L Olson; J S Schuman; K Singh; D Vollrath; G Wollstein; D J Zack; M Brilliant; A J Sit; W G Christen; J Fingert; J P Forman; E S Buys; P Kraft; K Zhang; R R Allingham; M A Pericak-Vance; J E Richards; M A Hauser; J L Haines; J L Wiggs; L R Pasquale
Journal:  Eye (Lond)       Date:  2014-03-07       Impact factor: 3.775

4.  Ischemic model of optic nerve injury.

Authors:  George A Cioffi
Journal:  Trans Am Ophthalmol Soc       Date:  2005

5.  Short-term variability of systemic blood pressure and submacular choroidal blood flow in eyes of patients with primary open-angle glaucoma.

Authors:  Asan Kochkorov; Konstantin Gugleta; Robert Katamay; Josef Flammer; Selim Orgul
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-04       Impact factor: 3.117

6.  Colour Doppler imaging and fluorescein filling defects of the optic disc in normal tension glaucoma.

Authors:  N Plange; A Remky; O Arend
Journal:  Br J Ophthalmol       Date:  2003-06       Impact factor: 4.638

7.  Increased levels of Helicobacter pylori IgG antibodies in aqueous humor of patients with primary open-angle and exfoliation glaucoma.

Authors:  Jannis Kountouras; Nikolaos Mylopoulos; Anastasios G P Konstas; Christos Zavos; Dimitrios Chatzopoulos; Anna Boukla
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-10-24       Impact factor: 3.117

8.  Color Doppler imaging and pattern visual evoked potential in normal tension glaucoma and hypertension glaucoma.

Authors:  Yisheng Zhong; Yingjun Min; Ying Jiang; Yu Cheng; Jiao Qin; Xi Shen
Journal:  Doc Ophthalmol       Date:  2009-09-12       Impact factor: 2.379

9.  Microvascular endothelial function and severity of primary open angle glaucoma.

Authors:  S M I Bukhari; K Y Kiu; R Thambiraja; S Sulong; A H G Rasool; A T Liza-Sharmini
Journal:  Eye (Lond)       Date:  2016-08-19       Impact factor: 3.775

Review 10.  Eyeing endothelins: a cellular perspective.

Authors:  Ganesh Prasanna; Santosh Narayan; Raghu R Krishnamoorthy; Thomas Yorio
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.